8EQF

cryoEM structure of a broadly neutralizing anti-SARS-CoV-2 antibody STI-9167

Summary for 8EQF

• Entry DOI: 10.2210/pdb8eqf/pdb
• EMDB information: 28537 29227
• Descriptor: Spike protein S1, Fab heavy chain, Fab light chain, ... (4 entities in total)
• Functional Keywords: antibody, sars-cov-2, immune system
• Biological source: Severe acute respiratory syndrome coronavirus 2; More
• Total number of polymer chains: 3
• Total formula weight: 47777.22

Authors

Bajic, G. (deposition date: 2022-10-07, release date: 2023-10-11, Last modification date: 2025-05-21)

Primary citation

Atanasoff, K.E.,Brambilla, L.,Adelsberg, D.C.,Kowdle, S.,Stevens, C.S.,Slamanig, S.,Hung, C.T.,Fu, Y.,Lim, R.,Tran, L.,Allen, R.,Sun, W.,Duty, J.A.,Bajic, G.,Lee, B.,Tortorella, D.
An in vitro experimental pipeline to characterize the epitope of a SARS-CoV-2 neutralizing antibody.
Mbio, 15:e0247723-e0247723, 2024

PubMed Abstract: The COVID-19 pandemic remains a significant public health concern for the global population; the development and characterization of therapeutics, especially ones that are broadly effective, will continue to be essential as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) variants emerge. Neutralizing monoclonal antibodies remain an effective therapeutic strategy to prevent virus infection and spread so long as they recognize and interact with circulating variants. The epitope and binding specificity of a neutralizing anti-SARS-CoV-2 Spike receptor-binding domain antibody clone against many SARS-CoV-2 variants of concern were characterized by generating antibody-resistant virions coupled with cryo-EM structural analysis and VSV-spike neutralization studies. This workflow can serve to predict the efficacy of antibody therapeutics against emerging variants and inform the design of therapeutics and vaccines.

PubMed: 38054729
DOI: 10.1128/mbio.02477-23

Experimental method

ELECTRON MICROSCOPY (3.16 Å)